596 related articles for article (PubMed ID: 18513356)
1. In vitro interactions of tobramycin with various nonantibiotics against Pseudomonas aeruginosa and Burkholderia cenocepacia.
Treerat P; Widmer F; Middleton PG; Iredell J; George AM
FEMS Microbiol Lett; 2008 Aug; 285(1):40-50. PubMed ID: 18513356
[TBL] [Abstract][Full Text] [Related]
2. Use of breakpoint combination sensitivity testing as a simple and convenient method to evaluate the combined effects of ceftazidime and tobramycin on Pseudomonas aeruginosa and Burkholderia cepacia complex isolates in vitro.
Tunney MM; Scott EM
J Microbiol Methods; 2004 Apr; 57(1):107-14. PubMed ID: 15003693
[TBL] [Abstract][Full Text] [Related]
3. Cystic fibrosis infections: treatment strategies and prospects.
George AM; Jones PM; Middleton PG
FEMS Microbiol Lett; 2009 Nov; 300(2):153-64. PubMed ID: 19674113
[TBL] [Abstract][Full Text] [Related]
4. Sputum antibiotic concentrations: implications for treatment of cystic fibrosis lung infection.
Moriarty TF; McElnay JC; Elborn JS; Tunney MM
Pediatr Pulmonol; 2007 Nov; 42(11):1008-17. PubMed ID: 17902147
[TBL] [Abstract][Full Text] [Related]
5. Effect of antibiotic co-administration on young and mature biofilms of cystic fibrosis clinical isolates: the importance of the biofilm model.
Tré-Hardy M; Macé C; El Manssouri N; Vanderbist F; Traore H; Devleeschouwer MJ
Int J Antimicrob Agents; 2009 Jan; 33(1):40-5. PubMed ID: 18801647
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of antibiotic combinations against Pseudomonas aeruginosa biofilm and planktonic cultures.
Tré-Hardy M; Vanderbist F; Traore H; Devleeschouwer MJ
Int J Antimicrob Agents; 2008 Apr; 31(4):329-36. PubMed ID: 18280117
[TBL] [Abstract][Full Text] [Related]
7. Antibiotic susceptabilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions.
Hill D; Rose B; Pajkos A; Robinson M; Bye P; Bell S; Elkins M; Thompson B; Macleod C; Aaron SD; Harbour C
J Clin Microbiol; 2005 Oct; 43(10):5085-90. PubMed ID: 16207967
[TBL] [Abstract][Full Text] [Related]
8. Antimicrobial activity of fosfomycin and tobramycin in combination against cystic fibrosis pathogens under aerobic and anaerobic conditions.
McCaughey G; McKevitt M; Elborn JS; Tunney MM
J Cyst Fibros; 2012 May; 11(3):163-72. PubMed ID: 22138067
[TBL] [Abstract][Full Text] [Related]
9. Molecular epidemiology of Pseudomonas aeruginosa, Burkholderia cepacia complex and methicillin-resistant Staphylococcus aureus in a cystic fibrosis center.
Campana S; Taccetti G; Ravenni N; Masi I; Audino S; Sisi B; Repetto T; Döring G; de Martino M
J Cyst Fibros; 2004 Aug; 3(3):159-63. PubMed ID: 15463902
[TBL] [Abstract][Full Text] [Related]
10. Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa.
Herrmann G; Yang L; Wu H; Song Z; Wang H; Høiby N; Ulrich M; Molin S; Riethmüller J; Döring G
J Infect Dis; 2010 Nov; 202(10):1585-92. PubMed ID: 20942647
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of long-term co-administration of tobramycin and clarithromycin in a mature biofilm model of cystic fibrosis clinical isolates of Pseudomonas aeruginosa.
Tré-Hardy M; Traore H; El Manssouri N; Vanderbist F; Vaneechoutte M; Devleeschouwer MJ
Int J Antimicrob Agents; 2009 Oct; 34(4):370-4. PubMed ID: 19505804
[TBL] [Abstract][Full Text] [Related]
12. Liposomal bismuth-ethanedithiol formulation enhances antimicrobial activity of tobramycin.
Halwani M; Blomme S; Suntres ZE; Alipour M; Azghani AO; Kumar A; Omri A
Int J Pharm; 2008 Jun; 358(1-2):278-84. PubMed ID: 18448284
[TBL] [Abstract][Full Text] [Related]
13. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis.
Burns JL; Van Dalfsen JM; Shawar RM; Otto KL; Garber RL; Quan JM; Montgomery AB; Albers GM; Ramsey BW; Smith AL
J Infect Dis; 1999 May; 179(5):1190-6. PubMed ID: 10191222
[TBL] [Abstract][Full Text] [Related]
14. Distribution and transmission of Pseudomonas aeruginosa and Burkholderia cepacia in a hospital ward.
Döring G; Jansen S; Noll H; Grupp H; Frank F; Botzenhart K; Magdorf K; Wahn U
Pediatr Pulmonol; 1996 Feb; 21(2):90-100. PubMed ID: 8882212
[TBL] [Abstract][Full Text] [Related]
15. Pseudomonas aeruginosa and Burkholderia cenocepacia infections in patients affected by cystic fibrosis: serum resistance and antibody response.
Savoia D; Deplano C; Zucca M
Immunol Invest; 2008; 37(1):19-27. PubMed ID: 18214797
[TBL] [Abstract][Full Text] [Related]
16. Development of a rapid colorimetric time-kill assay for determining the in vitro activity of ceftazidime and tobramycin in combination against Pseudomonas aeruginosa.
Moriarty F; Elborn S; Tunney M
J Microbiol Methods; 2005 May; 61(2):171-9. PubMed ID: 15722142
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of doripenem against Pseudomonas aeruginosa and Burkholderia cepacia isolates from both cystic fibrosis and non-cystic fibrosis patients.
Traczewski MM; Brown SD
Antimicrob Agents Chemother; 2006 Feb; 50(2):819-21. PubMed ID: 16436756
[TBL] [Abstract][Full Text] [Related]
18. Development of antibiotic resistance in Pseudomonas aeruginosa during two decades of antipseudomonal treatment at the Danish CF Center.
Ciofu O; Giwercman B; Pedersen SS; Høiby N
APMIS; 1994 Sep; 102(9):674-80. PubMed ID: 7946270
[TBL] [Abstract][Full Text] [Related]
19. Aminoglycoside therapy against Pseudomonas aeruginosa in cystic fibrosis: a review.
Ratjen F; Brockhaus F; Angyalosi G
J Cyst Fibros; 2009 Dec; 8(6):361-9. PubMed ID: 19747887
[TBL] [Abstract][Full Text] [Related]
20. Influence of gentamicin and tobramycin on binary biofilm formation by co-cultures of Burkholderia cepacia and Pseudomonas aeruginosa.
Al-Bakri AG; Gilbert P; Allison DG
J Basic Microbiol; 2005; 45(5):392-6. PubMed ID: 16187262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]